Krystal Biotech Future Growth
Future criteria checks 5/6
Krystal Biotech is forecast to grow earnings and revenue by 34.2% and 33% per annum respectively. EPS is expected to grow by 32.6% per annum. Return on equity is forecast to be 16.6% in 3 years.
Key information
34.2%
Earnings growth rate
32.6%
EPS growth rate
Biotechs earnings growth | 28.4% |
Revenue growth rate | 33.0% |
Future return on equity | 16.6% |
Analyst coverage | Good |
Last updated | 11 Sep 2024 |
Recent future growth updates
Recent updates
Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
Jun 17Krystal Biotech EPS misses by $0.16
May 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 670 | 316 | 292 | 238 | 7 |
12/31/2025 | 493 | 201 | 184 | 186 | 9 |
12/31/2024 | 294 | 77 | 83 | 83 | 9 |
6/30/2024 | 166 | 106 | -23 | -17 | N/A |
3/31/2024 | 96 | 57 | -54 | -47 | N/A |
12/31/2023 | 51 | 11 | -101 | -89 | N/A |
9/30/2023 | 9 | -30 | -119 | -104 | N/A |
6/30/2023 | N/A | -140 | -130 | -102 | N/A |
3/31/2023 | N/A | -135 | -152 | -111 | N/A |
12/31/2022 | N/A | -140 | -154 | -101 | N/A |
9/30/2022 | N/A | -130 | -188 | -99 | N/A |
6/30/2022 | N/A | -115 | -182 | -87 | N/A |
3/31/2022 | N/A | -104 | -137 | -54 | N/A |
12/31/2021 | N/A | -70 | -116 | -48 | N/A |
9/30/2021 | N/A | -58 | -70 | -35 | N/A |
6/30/2021 | N/A | -52 | -52 | -35 | N/A |
3/31/2021 | N/A | -43 | -45 | -30 | N/A |
12/31/2020 | N/A | -32 | -41 | -26 | N/A |
9/30/2020 | N/A | -27 | -35 | -25 | N/A |
6/30/2020 | N/A | -22 | -29 | -23 | N/A |
3/31/2020 | N/A | -20 | -28 | -22 | N/A |
12/31/2019 | N/A | -19 | -25 | -19 | N/A |
9/30/2019 | N/A | -17 | -21 | -15 | N/A |
6/30/2019 | N/A | -16 | -18 | -13 | N/A |
3/31/2019 | N/A | -13 | -14 | -10 | N/A |
12/31/2018 | N/A | -11 | -12 | -9 | N/A |
9/30/2018 | N/A | -9 | -9 | -8 | N/A |
6/30/2018 | N/A | -11 | -7 | -7 | N/A |
3/31/2018 | N/A | -10 | N/A | -6 | N/A |
12/31/2017 | N/A | -8 | N/A | -4 | N/A |
9/30/2017 | N/A | -7 | N/A | -3 | N/A |
6/30/2017 | N/A | -2 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KRYS's forecast earnings growth (34.2% per year) is above the savings rate (2.5%).
Earnings vs Market: KRYS's earnings (34.2% per year) are forecast to grow faster than the US market (15.2% per year).
High Growth Earnings: KRYS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: KRYS's revenue (33% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: KRYS's revenue (33% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KRYS's Return on Equity is forecast to be low in 3 years time (16.6%).